A 2026 paper in Liver International reports the EXCEL Phase 4 trial: a multicenter, double-blind, randomized, placebo-controlled study of essential phospholipids (EPL) - a purified soy extract whose core component is dilinoleoylphosphatidylcholine - in people with MASLD and metabolic comorbidities. Across 15 centers in Germany and Poland, 193 participants were randomized to EPL at 1,800 milligrams a day plus standard lifestyle guidance, or placebo plus the same guidance, with liver fat measured by CAP (controlled attenuation parameter) over six months.
The trial’s design is the part worth naming first, because it is the strongest structure a supplement can be tested in: double-blind, randomized, placebo-controlled, and - critically - the placebo group got the same lifestyle intervention, so any difference between the arms is the supplement’s contribution, not the diet’s. That design is what separates a credible supplement result from an anecdote.
Why this trial matters for the supplement category
Essential phospholipids have a long history as an over-the-counter liver aid, mostly on small studies. The EXCEL trial is the large, controlled evidence the category has been missing - and the fact that it is a Phase 4 trial, run after the product already exists, is itself a marker of how the field is catching up with supplement claims. The trial’s endpoints include liver fat by CAP, quality of life, and metabolic markers, with follow-up three months after treatment stops.
The honest boundary is the one every supplement trial shares: a controlled result in one population does not make the supplement a treatment, and the lifestyle arm in both groups is a reminder that the guidance - not the pill - is the foundation. The trial asks whether EPL adds to that foundation, which is the right question and a different one from whether it replaces it.
Where the plate still sits
The EXCEL design makes the plate’s role unusually visible, because both arms received the same standardized lifestyle intervention. That is the trial itself saying the food guidance is the baseline, and the supplement is the add-on being tested against that baseline. The Recommended column - salmon, legumes, whole grains, olive oil, vegetables - is the same kind of baseline a reader can build without a prescription.
The specific numbers make the pattern concrete. Rolled oats sit in Recommended at about 10 grams of fiber per 100 grams; fatty fish like salmon rate Recommended at roughly 1.3 grams of saturated fat per 100 grams with omega-3s; olive oil and walnuts bring the unsaturated fat. These are the foods that form the lifestyle foundation the trial assumes.
How our editorial team read this
We read supplement trials with the strictest bar on this site, because the category is where overclaiming does the most damage. Our data editor verified the trial structure - double-blind, placebo-controlled, with the same lifestyle arm in both groups - and we kept every claim at the level the authors use. We did not present EPL as a treatment, and we did not let a controlled result read as a substitute for the food guidance.
What we did do is give the trial the credit its design earns - it is the kind of evidence the supplement category has needed - while keeping the plate as the foundation the trial itself assumed. The honest line is that a well-designed supplement trial is good science, and the food baseline it tested against is the part a reader controls.
The practical takeaway
For someone with MASLD, the EXCEL trial is a reason to read supplement claims against controlled evidence rather than packaging, and a reminder that the lifestyle arm in both groups is the foundation. The Recommended column is that foundation; the supplement is a clinician-discussed add-on at best. The database covers the food; the trial covers the evidence; the reader owns the baseline.